


## IN THE CLAIMS

Please cancel claims 7, 9-10 and 20 and amend the claims, without prejudice or disclaimer, as indicated below.

1. Cancelled.

2. (Currently amended) A compound having the having the formula:



wherein R is either H or a charged ligand containing from 1 to 6 carbon atoms;

wherein R' is either H or a charged ligand containing from 1 to 6 carbon atoms; and

wherein at least one of R and R' is a charged ligand ~~containing from 1 to 6 carbon atoms,~~

with the proviso that when R or R' is H, the other of R or R' is a charged ligand containing 1, 2, 3, 5 or 6 carbon atoms.

3. (Previously presented) The compound of Claim 2, wherein at least one of R and R' is a charged ligand containing at least one  $\text{SO}_3^-$  group.


4. (Currently amended) The compound of Claim 2, wherein at least one of R and R' is a straight chain or branched alkyl group containing 1, 3, 4, 5, or 6 carbon atoms and at least one  $\text{SO}_3^-$  group.

5. (Previously presented) The compound of Claim 2, wherein at least one of R and R' is an aryl group containing at least one  $\text{SO}_3^-$  group.

6. (Currently amended) The compound of Claim 5, wherein the  $\text{SO}_3^-$  group is attached to a ring carbon atom.

7. Cancelled. (Previously presented) The compound of Claim 3, wherein the charged ligand containing at least one  $\text{SO}_3^-$  group comprises an aryl group and a  $\text{C}_1\text{-C}_6$  alkylene group attached at a first end to a ring carbon atom of said aryl group and attached at a second end to said  $\text{SO}_3^-$  group.

8. (Currently amended) A compound having the formula:



wherein R is H or alkyl;

wherein R' is H or alkyl;

wherein R'' is H or alkyl; and

wherein at least one of R, R' and R'' is alkyl, with the proviso that when two of R, R' and R'' are methyl, the other of R, R' and R'' is other than methyl.

9-10. Cancelled.

11. (Previously presented) The compound of Claim 2, wherein one of R or R' is H.

12. (Withdrawn) A method for inhibiting PDI by exposing cells expressing PDI to a compound according to claim 1 in an amount sufficient to inhibit PDI activity.

13. (Withdrawn) The method according to Claim 12, wherein PDI activity is measured by assaying L-selectin shedding from leucocytes or lymphocytes.

14. (Withdrawn) A method for treating a mammal for a viral infection propagated by PDI-mediated virion entry into host cells comprising administering to the mammal phenylarsine oxide (PAO) or a compound according to claim 1 in an amount sufficient to inhibit viral propagation.

15. (Withdrawn) The method of Claim 14, wherein the viral infection is an HIV infection.

16. (Withdrawn) A method for measuring the potency of a potential PDI inhibitor comprising assaying cell L-selectin shedding according to the Snezna L-Selectin Assay as a direct measure of inhibition potency.

17. (Withdrawn) The method of Claim 16, wherein leucocytes or lymphocytes are exposed to a potential PDI inhibitor, tagged with a labeled anti-L-selectin antibody and assayed for released L-selectin.

18. (Withdrawn) The method of Claim 16, wherein leucocytes or lymphocytes are prelabeled with a detectable anti-L-selectin antibody, contacted with a potential PDI inhibitor, and assayed for released selectin.

19. (Withdrawn) A method for determining optimum blood concentrations of a PDI inhibitor for treatment of a mammal for a viral infection according to Claim 14, comprising admixing a blood sample with a PDI inhibitor and assaying for leucocyte L-selectin shedding.

20-26. Cancelled.

27. (Withdrawn) A method for inhibiting PDI by exposing cells expressing PDI to a compound according to Claim 8 in an amount sufficient to inhibit PDI activity.


28-33. Cancelled.

34. (Withdrawn) A method for treating a mammal for a viral infection propagated by PDI-mediated virion entry into host cells comprising administering to the mammal phenylarsine oxide (PAO) or a compound according to claim 8 in an amount sufficient to inhibit viral propagation.

35. (Withdrawn) A method for determining optimum blood concentration of a PDI inhibitor for treatment of a mammal for a viral infection according to claim 15, comprising admixing a blood sample with PDI inhibitor and assaying for leucocyte L-selectin shedding.

The following claims are new:


36. (New) A compound having the having the formula:



wherein R and R' are either H or a charged ligand containing 1 to 6 carbon atoms and at least one  $\text{SO}_3^-$  group, with the proviso that R and R' are not both H.

37. (New) The compound of Claim 36, wherein at least one of R and R' is a straight chain or branched alkyl group.

38. (New) A compound having the having the formula:



wherein R and R' are either H or a charged ligand containing at least one  $\text{SO}_3^-$  group comprising an aryl group and a  $\text{C}_1\text{-C}_6$  alkylene group attached at a first end to a ring carbon atom of said aryl group and attached at a second end to said  $\text{SO}_3^-$  group, with the proviso that R and R' are not both H.